|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.58/-3.61
|
企业价值
1.25B
|
资产负债 |
每股账面净值
6.02
|
现金流量 |
现金流量率
--
|
损益表 |
收益
20.72M
|
每股收益
0.04
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/01 06:33 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |